查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576776

半乳糖血症市场：按类型、诊断、治疗方法、年龄层、最终用户、产品、测试、分析 - 2025-2030 年全球预测

Galactosemia Market by Type, Diagnosis Methods, Treatment Approaches, Age Group, End Users, Products, Tests And Assays - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年半乳糖血症市值为5.0425亿美元，预计到2024年将达到5.3154亿美元，复合年增长率为6.86%，到2030年将达到8.0253亿美元。

半乳糖血症是一种罕见的遗传性疾病，会影响人体处理和代谢半乳糖的能力，半乳糖是存在于牛奶和其他乳製品中的碳水化合物。此疾病的范围主要包括新生儿筛检、早期诊断和饮食管理，以预防认知障碍和肝损伤等严重併发症。由于迫切需要有效的诊断工具和治疗方法，因此该领域的市场研究需求非常大。这些开发成果的应用范围已扩展到医疗保健专业人员、医院、新生儿筛检计画和专业製药公司。一系列最终用途包括儿科医疗中心、遗传研究实验室和专注于遗传代谢疾病的营养服务。

主要市场统计
基准年[2023] 5.0425亿美元
预测年份 [2024] 53154万美元
预测年份 [2030] 80253万美元
复合年增长率（%） 6.86%

根据市场洞察，半乳糖血症领域的成长受到人们对遗传疾病认识的提高、遗传筛检技术的进步以及对罕见疾病研究的投资增加的显着影响。最新的商机在于创新营养食品、酵素替代疗法和个人化医疗方法的开发。利用这些机会的研究包括与研究机构建立策略伙伴关係以及投资先进的基因检测技术。然而，由于疾病罕见、研发成本高以及孤儿药法律规范等因素，市场成长受到限制。也存在一些挑战，例如某些地区的认知度较低以及专业医疗设施的可用性较低。

需要创新和研究的领域包括开发非侵入性筛检方法、探索基因治疗解决方案以及加强饮食管理通讯协定。公司还可以专注于制定教育计划，以促进早期发现和有效的管理策略。对市场性质的深入了解表明，由于对罕见疾病的宣传和政府支持的增加，这是一个利基市场，但正在稳步扩大。鼓励在这一领域运营的公司投资尖端研究，并与患者倡导组织合作，扩大市场范围并开发以患者为中心的解决方案。

市场动态：快速发展的半乳糖血症市场的关键市场洞察

供需的动态交互作用正在改变半乳糖血症市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大学术机构和生物技术公司在研究和药物开发方面的合作
    • 解决代谢紊乱的酵素替代疗法的开发和商业化
    • 增加患者倡导和支持团体推动研究和政策变革
    • 透过个人化医疗和标靶治疗方法的进步提供临床益处
  • 市场限制因素
    • 半乳糖血症的低盛行率限制了治疗的可能性
  • 市场机会
    • 扩大新生儿半乳糖血症的治疗选择并改善早期检测方法
    • 开发先进的诊断工具和标靶治疗，以解决成年半乳糖血症患者的特定酵素缺乏症
    • 为半乳糖血症患者提供遗传咨询和家庭支持服务的创新方法
  • 市场挑战
    • 由于缺乏对半乳糖血症的认识和及时诊断而延误治疗

波特的五力：驾驭半乳糖血症市场的策略工具

波特的五力架构是了解半乳糖血症市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解半乳糖血症市场的外部影响

外在宏观环境因素在塑造半乳糖血症市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解半乳糖血症市场的竞争格局

对半乳糖血症市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵半乳糖血症市场供应商绩效评估

FPNV 定位矩阵是评估半乳糖血症市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製半乳糖血症市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，半乳糖血症市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大学术机构与生物技术公司在研究和药物开发方面的合作
      • 解决代谢紊乱的酵素替代疗法的开发和商业化
      • 越来越多的患者倡导和支持团体推动研究和政策变革
      • 个人化医疗和标靶治疗方法的进步将带来临床益处
    • 抑制因素
      • 半乳糖血症的低盛行率限制了治疗和治疗的可能性
    • 机会
      • 扩大新生儿半乳糖血症的治疗选择并改善早期检测方法
      • 开发先进的诊断工具和标靶治疗治疗，以解决成人半乳糖血症患者的特定酵素缺乏问题
      • 为半乳糖血症患者提供遗传咨询和家庭支持服务的创新方法
    • 任务
      • 对半乳糖血症缺乏认识和及时诊断导致治疗延误
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章半乳糖血症市场：依类型

  • 经典半乳糖血症
    • 强风缺乏症
    • GALK缺乏症
    • GALT缺乏症
  • 临床变异
  • 杜阿尔特变种

第七章依诊断方法分類的半乳糖血症市场

  • 酵素测定
  • 基因检测
  • 新生儿筛检测试
    • 足跟采血试验
    • 质谱分析

第八章半乳糖血症市场（依治疗方法）

  • 膳食管理
    • 补充品
    • 半乳糖限制饮食
    • 大豆配方奶粉
  • 酵素替代疗法
  • 基因治疗

第九章半乳糖血症市场：依年龄组

  • 成人
  • 孩子们
  • 婴儿
  • 新生

第 10 章 半乳糖血症市场：依最终使用者分类

  • 学术机构
  • 诊断实验室
    • 临床实验室
    • 研究室
  • 医院
    • 私立医院
    • 公立医院

第十一章半乳糖市场：副产品

  • 数学公式
    • 不含乳糖
    • 大豆配方奶粉
  • 药品
  • 补充品
    • 补充品
    • 维生素补充品

第 12 章。

  • 确认测试
    • 脱氧核糖核酸测试
    • 酵素测定
  • 后续测试
  • 筛检测试

第十三章美洲半乳糖市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太半乳糖血症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲半乳糖市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C629188A1

The Galactosemia Market was valued at USD 504.25 million in 2023, expected to reach USD 531.54 million in 2024, and is projected to grow at a CAGR of 6.86%, to USD 802.53 million by 2030.

Galactosemia is a rare genetic disorder affecting the body's ability to process and metabolize galactose, a sugar found in milk and other dairy products. The scope of this condition primarily involves newborn screening, early diagnosis, and dietary management to prevent severe complications such as cognitive impairment and liver damage. The necessity for market research in this area is pronounced due to the critical need for effective diagnostic tools and treatments. The application of these developments extends to healthcare professionals, hospitals, newborn screening programs, and specialty pharmaceutical companies. End-use scope includes pediatric care centers, genetic research institutions, and dietetic services focused on inherited metabolic disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 504.25 million
Estimated Year [2024] USD 531.54 million
Forecast Year [2030] USD 802.53 million
CAGR (%) 6.86%

Market insights indicate that growth in the galactosemia space is significantly influenced by rising awareness of genetic disorders, advancements in genetic screening technologies, and increasing investment in rare disease research. The latest opportunities lie in the development of innovative dietary supplements, enzyme replacement therapies, and personalized medicine approaches. Recommendations for leveraging these opportunities include forming strategic partnerships with research institutions and investing in advanced genetic testing technologies. However, limitations in market growth stem from factors such as the rarity of the condition, high research and development costs, and stringent regulatory frameworks for orphan drugs. The challenging factors also include the lack of awareness in certain regions and limited availability of specialized healthcare facilities.

Areas ripe for innovation and research include the development of non-invasive screening methods, exploring gene therapy solutions, and enhancing dietary management protocols. Businesses could also focus on creating educational programs to promote early detection and effective management strategies. Insight into the nature of the market reveals it to be niche but steadily expanding due to increased advocacy and government support for rare diseases. Companies operating in this space are advised to invest in cutting-edge research and collaborate with patient advocacy groups to expand market reach and develop patient-centric solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Galactosemia Market

The Galactosemia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing collaborations between academic institutions and biotech firms for research and drug development
    • Development and commercialization of enzyme replacement therapies to address metabolic disorders
    • Increasing patient advocacy and support groups driving research and policy changes
    • Advancements in personalized medicine and targeted treatment approaches, offering clinical benefits
  • Market Restraints
    • Low prevalence of galactosemia limiting the potential for treatments and therapies
  • Market Opportunities
    • Expanding treatment options and improving early detection methods for galactosemia in neonates
    • Developing advanced diagnostic tools and targeted therapies to address specific enzyme deficiencies in adult patients with galactosemia
    • Innovative approaches to genetic counseling and family support services for those impacted by galactosemia
  • Market Challenges
    • Lack of awareness and timely diagnosis of galactosemia leading to delayed treatment

Porter's Five Forces: A Strategic Tool for Navigating the Galactosemia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Galactosemia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Galactosemia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Galactosemia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Galactosemia Market

A detailed market share analysis in the Galactosemia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Galactosemia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Galactosemia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Galactosemia Market

A strategic analysis of the Galactosemia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Galactosemia Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, Audentes Therapeutics, BioMarin Pharmaceutical Inc., BridgeBio Pharma, Erytech Pharma, GlaxoSmithKline, Hospira, Johnson & Johnson, LogicBio Therapeutics, Moderna, Novartis, Orphalan, Pfizer, Roche, Sanofi, Sarepta Therapeutics, Ultragenyx Pharmaceutical Inc., uniQure, and Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Galactosemia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Classic Galactosemia, Clinical Variant, and Duarte Variant. The Classic Galactosemia is further studied across GALE Deficiency, GALK Deficiency, and GALT Deficiency.
  • Based on Diagnosis Methods, market is studied across Enzyme Assay, Genetic Testing, and Newborn Screening Tests. The Newborn Screening Tests is further studied across Heel Prick Test and Mass Spectrometry.
  • Based on Treatment Approaches, market is studied across Dietary Management, Enzyme Replacement Therapy, and Gene Therapy. The Dietary Management is further studied across Calcium Supplements, Galactose-Restricted Diet, and Soy-Based Formula.
  • Based on Age Group, market is studied across Adults, Children, Infants, and Newborns.
  • Based on End Users, market is studied across Academic Institutions, Diagnostic Laboratories, and Hospitals. The Diagnostic Laboratories is further studied across Clinical Laboratories and Research Laboratories. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Products, market is studied across Formulas, Pharmaceuticals, and Supplements. The Formulas is further studied across Lactose-Free Formula and Soy-Based Formula. The Supplements is further studied across Calcium Supplements and Vitamin Supplements.
  • Based on Tests And Assays, market is studied across Confirmatory Tests, Follow-Up Tests, and Screening Tests. The Confirmatory Tests is further studied across DNA Testing and Enzyme Assays.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing collaborations between academic institutions and biotech firms for research and drug development
      • 5.1.1.2. Development and commercialization of enzyme replacement therapies to address metabolic disorders
      • 5.1.1.3. Increasing patient advocacy and support groups driving research and policy changes
      • 5.1.1.4. Advancements in personalized medicine and targeted treatment approaches, offering clinical benefits
    • 5.1.2. Restraints
      • 5.1.2.1. Low prevalence of galactosemia limiting the potential for treatments and therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding treatment options and improving early detection methods for galactosemia in neonates
      • 5.1.3.2. Developing advanced diagnostic tools and targeted therapies to address specific enzyme deficiencies in adult patients with galactosemia
      • 5.1.3.3. Innovative approaches to genetic counseling and family support services for those impacted by galactosemia
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and timely diagnosis of galactosemia leading to delayed treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Galactosemia Market, by Type

  • 6.1. Introduction
  • 6.2. Classic Galactosemia
    • 6.2.1. GALE Deficiency
    • 6.2.2. GALK Deficiency
    • 6.2.3. GALT Deficiency
  • 6.3. Clinical Variant
  • 6.4. Duarte Variant

7. Galactosemia Market, by Diagnosis Methods

  • 7.1. Introduction
  • 7.2. Enzyme Assay
  • 7.3. Genetic Testing
  • 7.4. Newborn Screening Tests
    • 7.4.1. Heel Prick Test
    • 7.4.2. Mass Spectrometry

8. Galactosemia Market, by Treatment Approaches

  • 8.1. Introduction
  • 8.2. Dietary Management
    • 8.2.1. Calcium Supplements
    • 8.2.2. Galactose-Restricted Diet
    • 8.2.3. Soy-Based Formula
  • 8.3. Enzyme Replacement Therapy
  • 8.4. Gene Therapy

9. Galactosemia Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Children
  • 9.4. Infants
  • 9.5. Newborns

10. Galactosemia Market, by End Users

  • 10.1. Introduction
  • 10.2. Academic Institutions
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Clinical Laboratories
    • 10.3.2. Research Laboratories
  • 10.4. Hospitals
    • 10.4.1. Private Hospitals
    • 10.4.2. Public Hospitals

11. Galactosemia Market, by Products

  • 11.1. Introduction
  • 11.2. Formulas
    • 11.2.1. Lactose-Free Formula
    • 11.2.2. Soy-Based Formula
  • 11.3. Pharmaceuticals
  • 11.4. Supplements
    • 11.4.1. Calcium Supplements
    • 11.4.2. Vitamin Supplements

12. Galactosemia Market, by Tests And Assays

  • 12.1. Introduction
  • 12.2. Confirmatory Tests
    • 12.2.1. DNA Testing
    • 12.2.2. Enzyme Assays
  • 12.3. Follow-Up Tests
  • 12.4. Screening Tests

13. Americas Galactosemia Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Galactosemia Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Galactosemia Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. Audentes Therapeutics
  • 4. BioMarin Pharmaceutical Inc.
  • 5. BridgeBio Pharma
  • 6. Erytech Pharma
  • 7. GlaxoSmithKline
  • 8. Hospira
  • 9. Johnson & Johnson
  • 10. LogicBio Therapeutics
  • 11. Moderna
  • 12. Novartis
  • 13. Orphalan
  • 14. Pfizer
  • 15. Roche
  • 16. Sanofi
  • 17. Sarepta Therapeutics
  • 18. Ultragenyx Pharmaceutical Inc.
  • 19. uniQure
  • 20. Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GALACTOSEMIA MARKET RESEARCH PROCESS
  • FIGURE 2. GALACTOSEMIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GALACTOSEMIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GALACTOSEMIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GALACTOSEMIA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GALACTOSEMIA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GALACTOSEMIA MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GALACTOSEMIA MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES GALACTOSEMIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES GALACTOSEMIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. GALACTOSEMIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. GALACTOSEMIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GALACTOSEMIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GALACTOSEMIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GALACTOSEMIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GALACTOSEMIA MARKET DYNAMICS
  • TABLE 7. GLOBAL GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GALACTOSEMIA MARKET SIZE, BY GALE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GALACTOSEMIA MARKET SIZE, BY GALK DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GALACTOSEMIA MARKET SIZE, BY GALT DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GALACTOSEMIA MARKET SIZE, BY CLINICAL VARIANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GALACTOSEMIA MARKET SIZE, BY DUARTE VARIANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GALACTOSEMIA MARKET SIZE, BY ENZYME ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GALACTOSEMIA MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GALACTOSEMIA MARKET SIZE, BY HEEL PRICK TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GALACTOSEMIA MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GALACTOSEMIA MARKET SIZE, BY CALCIUM SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GALACTOSEMIA MARKET SIZE, BY GALACTOSE-RESTRICTED DIET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GALACTOSEMIA MARKET SIZE, BY SOY-BASED FORMULA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GALACTOSEMIA MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GALACTOSEMIA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GALACTOSEMIA MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GALACTOSEMIA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GALACTOSEMIA MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GALACTOSEMIA MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GALACTOSEMIA MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GALACTOSEMIA MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GALACTOSEMIA MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GALACTOSEMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GALACTOSEMIA MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL GALACTOSEMIA MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL GALACTOSEMIA MARKET SIZE, BY FORMULAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL GALACTOSEMIA MARKET SIZE, BY LACTOSE-FREE FORMULA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL GALACTOSEMIA MARKET SIZE, BY SOY-BASED FORMULA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL GALACTOSEMIA MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL GALACTOSEMIA MARKET SIZE, BY CALCIUM SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL GALACTOSEMIA MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL GALACTOSEMIA MARKET SIZE, BY DNA TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL GALACTOSEMIA MARKET SIZE, BY ENZYME ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL GALACTOSEMIA MARKET SIZE, BY FOLLOW-UP TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL GALACTOSEMIA MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES GALACTOSEMIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC GALACTOSEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 184. AUSTRALIA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. INDIA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 202. INDIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 203. INDIA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 204. INDIA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 205. INDIA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 206. INDIA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. INDIA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 208. INDIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 209. INDIA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 210. INDIA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. INDIA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 214. INDIA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 215. INDONESIA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. INDONESIA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 217. INDONESIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 218. INDONESIA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 219. INDONESIA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 220. INDONESIA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 221. INDONESIA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. INDONESIA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 223. INDONESIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 224. INDONESIA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 225. INDONESIA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 226. INDONESIA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. INDONESIA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 229. INDONESIA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 230. JAPAN GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. JAPAN GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 232. JAPAN GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 233. JAPAN GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 234. JAPAN GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 235. JAPAN GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 236. JAPAN GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. JAPAN GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 238. JAPAN GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 239. JAPAN GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 240. JAPAN GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 241. JAPAN GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 242. JAPAN GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 243. JAPAN GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 244. JAPAN GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. MALAYSIA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. MALAYSIA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 247. MALAYSIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 248. MALAYSIA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 249. MALAYSIA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 250. MALAYSIA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 251. MALAYSIA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. MALAYSIA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 253. MALAYSIA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 254. MALAYSIA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 255. MALAYSIA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 256. MALAYSIA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 257. MALAYSIA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 258. MALAYSIA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 259. MALAYSIA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 260. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 262. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 264. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 266. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 267. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 268. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 269. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 270. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 272. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 274. PHILIPPINES GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 275. SINGAPORE GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SINGAPORE GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 277. SINGAPORE GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 278. SINGAPORE GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 279. SINGAPORE GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 280. SINGAPORE GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 281. SINGAPORE GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 282. SINGAPORE GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 283. SINGAPORE GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 284. SINGAPORE GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 285. SINGAPORE GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 286. SINGAPORE GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 287. SINGAPORE GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 288. SINGAPORE GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 289. SINGAPORE GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 296. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 297. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 298. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 299. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 300. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 302. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 304. SOUTH KOREA GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 305. TAIWAN GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. TAIWAN GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 307. TAIWAN GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 308. TAIWAN GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 309. TAIWAN GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 310. TAIWAN GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 311. TAIWAN GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 312. TAIWAN GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 313. TAIWAN GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 314. TAIWAN GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 315. TAIWAN GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 316. TAIWAN GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 317. TAIWAN GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 318. TAIWAN GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 319. TAIWAN GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 320. THAILAND GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. THAILAND GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 322. THAILAND GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 323. THAILAND GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 324. THAILAND GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 325. THAILAND GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 326. THAILAND GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 327. THAILAND GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 328. THAILAND GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 329. THAILAND GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 330. THAILAND GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 331. THAILAND GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 332. THAILAND GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 333. THAILAND GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 334. THAILAND GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 335. VIETNAM GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. VIETNAM GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 337. VIETNAM GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 338. VIETNAM GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 339. VIETNAM GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 340. VIETNAM GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 341. VIETNAM GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 342. VIETNAM GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 343. VIETNAM GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 344. VIETNAM GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 345. VIETNAM GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 346. VIETNAM GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 347. VIETNAM GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 348. VIETNAM GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 349. VIETNAM GALACTOSEMIA MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 350. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY CLASSIC GALACTOSEMIA, 2018-2030 (USD MILLION)
  • TABLE 352. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY DIAGNOSIS METHODS, 2018-2030 (USD MILLION)
  • TABLE 353. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY NEWBORN SCREENING TESTS, 2018-2030 (USD MILLION)
  • TABLE 354. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY TREATMENT APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 355. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 356. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 357. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 358. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 359. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 360. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 361. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY FORMULAS, 2018-2030 (USD MILLION)
  • TABLE 362. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 363. EUROPE, MIDDLE EAST & AFRICA GALACTOSEMIA MARKET SIZE, BY TESTS AND ASSAYS, 201